duloxetine hydrochloride

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Major Depressive Disorder

Conditions

Major Depressive Disorder

Trial Timeline

Aug 1, 2004 → Jan 1, 2005

NCT ID

NCT00479726

About duloxetine hydrochloride

duloxetine hydrochloride is a approved stage product being developed by Eli Lilly for Major Depressive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00479726. Target conditions include Major Depressive Disorder.

What happened to similar drugs?

20 of 20 similar drugs in Major Depressive Disorder were approved

Approved (20) Terminated (0) Active (0)

✅Mirtazapine TabletsSun PharmaceuticalApproved

✅DuloxetineEli LillyApproved

✅duloxetineEli LillyApproved

✅DuloxetineEli LillyApproved

✅Duloxetine hydrochlorideEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00071708	Pre-clinical	Completed	—	—	Major Depressive Disorder
NCT00960986	Approved	Completed	Aug 1, 2009	Apr 1, 2011	Major Depressive Disorder (MDD)
NCT00437125	Approved	Completed	Mar 1, 2007	Jul 1, 2009	Major Depressive Disorder
NCT00266643	Approved	Completed	Dec 1, 2005	Apr 1, 2007	Diabetic Neuropathy, Painful
NCT00583193	Phase 3	UNKNOWN	Dec 1, 2005	Jun 1, 2008	Posttraumatic Stress Disorders
NCT00191594	Phase 3	Completed	Mar 1, 2005	Aug 1, 2006	Major Depressive Disorder
NCT00191061	Approved	Completed	Oct 1, 2004	Jan 1, 2006	Depressive Disorder
NCT00479726	Approved	Completed	Aug 1, 2004	Jan 1, 2005	Major Depressive Disorder
NCT00036309	Phase 3	Completed	May 1, 2002	Jul 1, 2003	Depressive Disorder
NCT00036335	Phase 3	Completed	Mar 1, 2002	Jan 1, 2003	Depression

Competing Products

20 competing products in Major Depressive Disorder

See all competitors

Product	Company	Stage	Hype Score
Duloxetine Hydrochloride	Eli Lilly	Pre-clinical	26
LY2216684	Eli Lilly	Phase 1	29
LY2216684	Eli Lilly	Phase 1	29
Duloxetine	Eli Lilly	Phase 3	40
LY2216684 + Digoxin	Eli Lilly	Phase 1	29
Duloxetine + Paroxetine	Eli Lilly	Phase 3	40
Duloxetine + placebo	Eli Lilly	Phase 3	40
LY2216684 + Placebo + Escitalopram	Eli Lilly	Phase 2	35
FK949E	Astellas Pharma	Phase 1	29
quetiapine extended release (XR) + Placebo	Astellas Pharma	Phase 2	35
FK949E	Astellas Pharma	Phase 1	29
FK949E	Astellas Pharma	Phase 1	29
FK949E	Astellas Pharma	Phase 1	29
Mirtazapine Tablets	Sun Pharmaceutical	Approved	43
ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1	Ono Pharmaceutical	Phase 2	35
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	39
Pramipexole ER + Escitalopram	Cipla	Phase 2	42
LY2216684 + Sertraline	Eli Lilly	Phase 1	29
LY2216684 + Placebo + Lorazepam	Eli Lilly	Phase 1	29
LY2216684 + SSRI	Eli Lilly	Phase 3	40